Form D · Biotechnology
Viracta Subsidiary, Inc.
Cardiff, CA · CIK 0001416377
Offering snapshot reported Mar 10, 2021 · SEC filing
- Reported sold
- $65M Offering amount: $65M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 24, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 10, 2021 | Initial | $64,999,994 | No comparison | 26 | SEC filing |
| Dec 10, 2020 | Initial | $39,999,997 | No comparison | 14 | SEC filing |
| Nov 5, 2019 | Initial | $16,774,987 | No comparison | 21 | SEC filing |
| Feb 12, 2019 | Amendment | $10,695,495 | $8,695,495vs Dec 13, 2018 | 6 | SEC filing |
| Feb 12, 2019 | Initial | $5,714,363 | No comparison | 25 | SEC filing |
| Dec 13, 2018 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Jul 2, 2018 | Initial | $2,685,000 | No comparison | 27 | SEC filing |
| Apr 5, 2017 | Initial | $9,875,623 | No comparison | 9 | SEC filing |
| Apr 4, 2012 | Initial | $6,499,999 | No comparison | 10 | SEC filing |
| Aug 2, 2010 | Amendment | $16,064,150 | $10,064,151vs Feb 1, 2010 | 12 | SEC filing |
| Feb 1, 2010 | Initial | $5,999,999 | No comparison | 5 | SEC filing |
| Oct 23, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-391789
Source: Form D, filed Mar 10, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ronald Berenson | Director, Executive, Promoter |
| Daniel Chevallard | Executive |
| Frederick Dotzler | Director |
| Fred Dotzler | Director |
| Bryan Dunnivant | Director, Executive |
| Standish Fleming | Director |
| Richard Ghalie | Director |
| Paul Goddard | Director |
| Mark Handfelt | Executive |
| Michael Huang | Director |
| John P. Longenecker | Director, Executive |
| Naheed Misfeldt | Director |
| Samuel Murphy | Director |
| Susan Perrine | Executive |
| Roger Pomerantz | Director |
| Wayne Roe | Director |
| Gur Roshwalb | Director |
| Ivor Royston | Director, Executive |
| Tamara Seymour | Executive |
| Armen Shanafelt | Director |
| Barry Simon | Director |
| David Slack | Executive |
| Patrick Soon Shiong | Director |
| George Stamatoyannopoulos | Director |
| James Woody | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2533 S. Coast Highway 101, Suite 210
Cardiff, CA, 92007
Cardiff, CA, 92007